Clinical trial readout dates for Agios Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is March 2029.
| Phase 3 Mitapivat Non-Transfusion-dependent Alpha-Thalassemia; Non-Transfusion-dependent Beta-Thalassemia · NCT07517133 | March 2029 Recruiting |
| Phase 3 Mitapivat Matched Placebo Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Beta-Thalassemia · NCT07506863 | June 2029 Recruiting |
| Phase 3 Mitapivat Matched Placebo Sickle Cell Disease · NCT07656415 | August 2029 Recruiting |
| Phase 2/3 AG-236 Polycythemia Vera · NCT07859423 | August 2030 Not Yet Recruiting |
Agios Pharmaceuticals Inc. reported $1.18B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). Its net loss for that quarter was $65M; at that rate the cash would last about 18 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-05 |